secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2026-08-06T20:16:21+00:00
Accession:  0001559053-26-000021
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena reports Q2 net loss of $18.6M, revenue $1.0M; updates cash guidance to ~$259M
--------------------------------------------------------------------------------

- Net loss of $18.6M in Q2 2026 vs $125.8M loss in Q2 2025; basic EPS loss $0.36 vs $2.34.
- Total revenue $1.0M in Q2, $52.1M in H1 2026 (includes $50M Novo Nordisk milestone).
- Cash and restricted cash $289.1M at June 30, 2026; no debt.
- Updated FY 2026 year-end cash guidance to ~$259M (midpoint), down $14M from prior due to share repurchases.
- Repurchased 2,243,888 shares in H1 2026 for $22.3M under $100M program; $55M milestone from BMS possible by YE.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000155905326000021/0001559053-26-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000155905326000021/prta-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001559053-26-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer